Security key
00773J202
Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE)
CUSIP: 00773J202
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.0001 Par Value Per Share
- Shares outstanding
- 86,389,920
- Total 13F shares
- 80,976,878
- Share change
- +15,502,207
- Total reported value
- $2,652,563,796
- Put/Call ratio
- 7.9%
- Price per share
- $32.76
- Number of holders
- 152
- Value change
- +$541,005,178
- Number of buys
- 103
- Number of sells
- 40
Report period
Q4 2025
Institutions
152
Top holders
10
SYRE full security history
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Spyre Therapeutics, Inc. SEC filings
Spyre Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00773J202
Recent filing periods:
Top shareholders of SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.6%
from 13D/G
|
3,982,744
|
$66,750,788 | — | 30 Sep 2025 | |
| RTW INVESTMENTS, LP |
13F
13D/G
|
Company |
6.2%
from 13D/G
|
3,621,996
|
$60,704,653 | — | 30 Sep 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
4.6%
|
2,685,448
|
$40,335,429 | $0 | 31 Dec 2024 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
2.4%
|
1,892,200
|
$62,064,160 | -$42,895,840 | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
10%
|
9,060,144
|
$151,848,013 | — | 30 Sep 2025 | |
| Fairmount Funds Management LLC |
13F
3/4/5
|
Company · Director |
4.7%
|
4,018,101
|
$67,343,373 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.5%
|
3,050,730
|
$51,130,235 | — | 30 Sep 2025 | |
| Venrock Adviser, LLC |
13F
|
Company |
3.1%
|
2,685,448
|
$45,008,108 | — | 30 Sep 2025 | |
| BRAIDWELL LP |
13F
|
Company |
3%
|
2,578,404
|
$43,214,051 | — | 30 Sep 2025 | |
| Capital International Investors |
13F
|
Company |
2.8%
|
2,392,541
|
$40,098,987 | — | 30 Sep 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.4%
|
2,060,375
|
$34,531,885 | — | 30 Sep 2025 | |
| Commodore Capital LP |
13F
|
Company |
2.3%
|
1,988,084
|
$33,320,288 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.1%
|
1,785,206
|
$29,920,053 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.9%
|
1,640,312
|
$27,491,629 | — | 30 Sep 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.7%
|
1,467,266
|
$24,591,378 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
1.6%
|
1,419,299
|
$23,787,451 | — | 30 Sep 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
1.6%
|
1,388,854
|
$23,277,193 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.4%
|
1,229,445
|
$20,605,498 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
1,225,153
|
$20,536,009 | — | 30 Sep 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.3%
|
1,100,582
|
$18,445,754 | — | 30 Sep 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.2%
|
1,036,218
|
$17,367,014 | — | 30 Sep 2025 | |
| BAKER BROS. ADVISORS LP |
13F
3/4/5
|
Company · Director |
1.2%
|
1,000,000
|
$16,760,000 | — | 30 Sep 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.92%
|
795,275
|
$13,328,809 | — | 30 Sep 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.91%
|
788,788
|
$13,220,087 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.72%
|
620,620
|
$10,402,000 | — | 30 Sep 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.71%
|
613,665
|
$10,285,025 | — | 30 Sep 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
0.64%
|
548,712
|
$9,196,413 | — | 30 Sep 2025 | |
| Blackstone Inc. |
13F
|
Company |
0.58%
|
500,998
|
$8,396,726 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
442,036
|
$7,408,524 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.49%
|
425,345
|
$7,128,782 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.47%
|
408,199
|
$6,841,415 | — | 30 Sep 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.47%
|
404,362
|
$6,777,107 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.45%
|
385,589
|
$6,462,472 | — | 30 Sep 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
0.43%
|
368,598
|
$6,177,702 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.4%
|
344,803
|
$5,778,898 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.39%
|
334,722
|
$5,609,949 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.38%
|
329,533
|
$5,522,973 | — | 30 Sep 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.38%
|
326,081
|
$5,465,118 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.37%
|
315,909
|
$5,294,635 | — | 30 Sep 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
0.36%
|
308,212
|
$5,165,633 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.32%
|
275,984
|
$4,625,492 | — | 30 Sep 2025 | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
0.31%
|
264,317
|
$4,429,953 | — | 30 Sep 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.25%
|
215,746
|
$3,615,903 | — | 30 Sep 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.23%
|
200,753
|
$3,364,620 | — | 30 Sep 2025 | |
| Capital World Investors |
13F
|
Company |
0.23%
|
200,172
|
$3,354,883 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.19%
|
168,330
|
$2,821,212 | — | 30 Sep 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.18%
|
156,000
|
$2,614,560 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
135,960
|
$2,278,690 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.15%
|
131,876
|
$2,210,242 | — | 30 Sep 2025 | |
| Universal- Beteiligungs- und Servicegesellschaft mbH |
13F
|
Individual |
0.13%
|
110,456
|
$1,851,243 | — | 30 Sep 2025 |
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE) as of Q4 2025
As of 31 Dec 2025,
Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE) was held by
152 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
80,976,878 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., RTW INVESTMENTS, LP, VANGUARD GROUP INC, Fairmount Funds Management LLC, VR ADVISER, LLC, Capital International Investors, PERCEPTIVE ADVISORS LLC, Driehaus Capital Management LLC, and Commodore Capital LP.
This page lists
152
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
136
Q4 2025 holders
152
Holder diff
16
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.